PSORIASIS

This study followed 240 adults in Taiwan with moderate-to-severe plaque psoriasis for about 2 years. It compared how well the approved drug risankizumab kept skin clear compared to other similar biologic treatments that patients were already prescribed by their doctors. Researche…

This study tested whether a new intravenous drug called BI 655130 could safely reduce symptoms of palmoplantar pustulosis (PPP), a painful condition causing blisters and scaling on the palms and soles. In this 16-week trial, 59 adults with PPP received either the drug or a placeb…

This study tested if people with moderate-to-severe plaque psoriasis who responded very well to the drug guselkumab could safely receive their injections less often—every 16 weeks instead of every 8—and still keep their skin clear. It involved 880 participants and looked at skin …

This study asked 30 people with mild-to-moderate psoriasis which topical treatment they preferred: Wynzora cream or Enstilar foam. Participants had previously used the foam and then switched to the cream for four weeks. Researchers measured which treatment patients liked better, …

This study tested a treatment called hemoperfusion for people with severe psoriasis. It involved filtering a patient's blood through a special device (Efferon CT) to remove excess inflammatory proteins believed to drive the disease. The goal was to see if this procedure could saf…

This early-stage study tested a 4-week oral treatment called SAR441566 for people with mild to moderate psoriasis. The main goal was to check the treatment's safety and how well it was tolerated. Researchers also measured if it reduced the severity of skin lesions compared to a p…

This study tested a new drug called ASKP1240 in people with moderate to severe plaque psoriasis. The main goals were to check the drug's safety, how it moves through the body, and if it could improve skin symptoms. About 60 participants received either the drug or a placebo over …

This study tested whether the drug tofacitinib is safe and effective for treating several common autoimmune skin conditions in adolescents and adults with Down syndrome. Researchers wanted to see if reducing overactive immune signaling could improve skin health, quality of life, …

This small, completed study tested whether starting treatment for moderate-to-severe plaque psoriasis with double or quadruple the standard dose of the drug risankizumab could lead to better and longer-lasting skin clearance. Researchers wanted to see if these higher doses more e…

This study tested a special fabric called Lumiton that converts sunlight into therapeutic red and near-infrared light. It aimed to see if wearing clothes made from this fabric could help control symptoms of psoriasis, alopecia areata (hair loss), and polymorphous light eruption (…

This small study tested whether adding the common diabetes medication metformin to standard psoriasis treatment cyclosporine works better than cyclosporine alone. Researchers enrolled 32 adults with moderate to severe psoriasis to compare the two approaches. The goal was to see i…

This study offered children aged 6-17 with moderate to severe plaque psoriasis the option to continue taking the drug apremilast for up to four years after completing a previous trial. The main goal was to monitor the long-term safety of the medication in growing children, tracki…

This small, completed study tested whether medications used to treat HIV (reverse transcriptase inhibitors) could help control psoriasis. Researchers gave these drugs to 8 people with long-term plaque psoriasis to see if they could reduce skin inflammation and improve lesions. Th…

This study tested a new drug called BMS-986322 to see if it could safely reduce the skin plaques and symptoms of moderate-to-severe psoriasis. It involved 109 adults with significant psoriasis coverage and compared the drug's effects to a placebo over 12 weeks. The main goal was …

This study tested a new oral medication called SAR441566 to see if it could safely reduce the skin plaques and redness of moderate to severe psoriasis. Over 200 adults with the condition took different doses of the drug or a placebo pill for 12 weeks. Researchers measured how muc…

This study tested whether carefully reducing the dose of newer psoriasis medications (IL17 or IL23 inhibitors) works as well as continuing the standard dose. It involved 244 patients whose psoriasis was already well-controlled. The goal was to see if lower doses could maintain co…

This study tested whether tildrakizumab, an FDA-approved drug for moderate-to-severe psoriasis, could improve how well the heart's tiny blood vessels work. Researchers enrolled 36 adults with psoriasis who also had risk factors for heart disease. They used heart imaging scans to …

This study aimed to understand the safety and effectiveness of the drug Otezla when used by real patients in everyday doctor's offices. It followed over 1,000 people with psoriasis or psoriatic arthritis who were starting Otezla for the first time. The goal was to collect informa…

This study tested whether an oral medication called deucravacitinib could clear or nearly clear scalp psoriasis better than a placebo. It involved 154 adults with moderate-to-severe scalp psoriasis who had not gotten enough relief from topical creams. Researchers measured how wel…

This study tested a new topical ointment called SGX302, which is activated by visible light, to see if it could improve skin lesions in people with mild-to-moderate plaque psoriasis. Fifteen participants applied the treatment to their skin for an 18-week course. The main goal was…

This study tested whether adding an antidepressant to standard psoriasis medication works better than the psoriasis medication alone for people who have both psoriasis and depression or anxiety. Forty adults with moderate-to-severe psoriasis and significant depression/anxiety wer…

This study tested a new oral medication called AX-158 for people with mild to moderate plaque psoriasis. For 28 days, 31 participants took either the drug or a placebo pill, followed by a safety check for another month. The main goal was to see if the drug was safe and well-toler…

This study tested whether an artificial intelligence (AI) tool could help doctors more accurately diagnose a wide range of skin conditions, from common rashes to skin cancer. Sixteen doctors first diagnosed 29 skin image cases on their own, then reviewed the AI's suggestions to s…

This study tested a 12-week online wellness coaching program designed to improve mental health in adults with psoriasis or psoriatic arthritis. Participants received weekly guidance from a wellness professional to help improve sleep, physical activity, stress, and nutrition. The …

This study tested whether a medication called deucravacitinib could improve the daily life and well-being of people living with plaque psoriasis. It involved 180 adults with moderate-to-severe psoriasis who were already candidates for systemic treatment. Participants were randoml…

This study aimed to test a new questionnaire designed to measure the long-term life impact of moderate-to-severe psoriasis. 154 patients who were starting a standard psoriasis medication (risankizumab) completed the 30-question survey over 28 weeks. The goal was to see if the que…

This study aimed to understand and compare the experience of fatigue in people with psoriatic arthritis and those with skin psoriasis. Researchers enrolled 33 adult patients to complete questionnaires about their fatigue levels and quality of life. The goal was to see how fatigue…

This study followed 2,376 adults with moderate-to-severe plaque psoriasis for 5 years to understand how different treatments work in real-world settings. Researchers compared the safety and effectiveness of the drug secukinumab against other approved therapies like biologics, pil…

This small study aimed to understand the connection between nerve sensitivity, skin blood flow, and the pain many people with psoriasis experience. Researchers measured how blood vessels in the skin of 20 patients with psoriasis reacted to certain substances, comparing a psoriasi…

This study aimed to see if newer psoriasis medications (IL17 or IL23 inhibitors) improve markers of artery stiffness and heart health over one year. It observed 66 patients with moderate-to-severe psoriasis who were already starting these treatments. The main goal was to measure …

This study aimed to create and test a decision-making tool for patients with psoriasis or psoriatic arthritis. The tool was designed to help patients and their doctors work together when starting or switching to a new medication. Researchers tested how satisfied patients and doct…

This small, early-stage study aimed to understand how a potential new psoriasis pill, Hemay005, is processed by the body in people with different levels of kidney function. It involved 26 adults with normal, mild, or moderate kidney impairment who took a single dose. The main goa…

This study aimed to better understand what causes psoriasis by looking at skin samples. Researchers examined 40 people with psoriasis to measure two specific immune system components in their skin. The goal was to see if these components are linked to how severe the psoriasis is,…

This small, completed study aimed to understand how a potential new psoriasis drug, Hemay005, interacts with a common sedative (midazolam) in the body. It involved 20 healthy adults to check if the drug affects heart rhythm and measures of inflammation. The main goal was to gathe…

This study aimed to understand if there is a connection between psoriasis, a chronic skin condition, and the health of a person's gums. Researchers compared 226 people with psoriasis to a group without it, checking their oral health and asking about their quality of life. The goa…

This study looked at whether two common psoriasis medications, Secukinumab and Adalimumab, affect bone health. Researchers followed 100 adults with moderate-to-severe psoriasis to see if their bone density changed over time while on one of these treatments. The goal was to gather…

This study aimed to understand how the chronic inflammation from psoriasis might increase a person's risk for heart disease and diabetes. Researchers followed 386 adults with psoriasis for up to 4 years, performing regular blood tests, heart scans, and optional skin biopsies. The…